FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W82259717> ?p ?o ?g. }

• W82259717 endingPage "59" @default.
• W82259717 startingPage "145" @default.
• W82259717 abstract "1) Should dexrazoxane be used routinely in patients with advanced or metastatic cancer who are at risk of developing cardio toxicity when receiving chemotherapy containing doxorubicin or epirubicin? 2) Do the available data support the use of dexrazoxane when anthracyclines are being used in the adjuvant setting for patients at risk of developing cardiotoxicity?To make recommendations regarding the use of dexrazoxane to prevent cardiotoxicity in patients with nonhematological malignancies who are receiving anthracycline- containing chemotherapy.Clinical and subclinical cardiotoxicity, noncardiac toxicity and impact on efficacy outcomes such as response and overall survival are considered.Evidence was selected, reviewed and synthesized by 2 members of Cancer Care Ontario's Systemic Treatment Disease Site Group (STDSG), formerly the Systemic Treatment Program Committee. Drafts of this document have been circulated and reviewed by members of the STDSG. The STDSG comprises medical oncologists, pharmacists, supportive care personnel and administrators. Community representatives did not participate in the development of this guideline, but they will be included in future guidelines.Seven randomized controlled trials (RCTs), 2 with placebo control, were available for analysis.Data for clinical cardiotoxicity from 6 trials were pooled (n = 1070). The meta-analysis indicated that the risk of experiencing clinical cardiotoxicity was significantly reduced by dexrazoxane (risk ratio 0.24; 95% confidence interval [CI] 0.11 to 0.52; p = 0.00031). There was no significant benefit shown in individual trials for objective response or survival.One of the RCTs revealed a significantly lower objective response rate in the dexrazoxane arm. However, a meta-analysis of objective response across 5 trials of breast cancer patients (n = 818) did not confirm this effect (odds ratio 0.85; 95% CI 0.61 to 1.18; p = 0.33). The use of dexrazoxane increased the incidence of myelosuppression and other noncardiac toxicities, but these were generally mild.The evidence supports the use of dexrazoxane to provide protection against the cardiotoxicity associated with conventional-dose doxorubicin in patients with advanced but anthracycline-sensitive cancer, in whom the continued use of anthracycline-containing chemotherapy is indicated in the opinion of the treating physician and who have received 300 mg/m2 or more of doxorubicin. The evidence supports the use dexrazoxane to provide protection against the cardiotoxicity associated with conventional-dose epirubicin in patients with advanced but anthracycline-sensitive cancer, in whom the continued use of anthracycline-containing chemotherapy is indicated in the opinion of the treating physicians. There are no data indicating the optimal cumulative dose of epirubicin at which dexrazoxane should be instituted. For doxorubicin, use of dexrazoxane is recommended after the cumulative dose reaches 300 mg/m2 (i.e., 55% of the recommended maximum). A similar formula could be used for epirubicin, that is, institution of dexrazoxane when the cumulative dose of epirubicin reaches 550 mg/m2, as the recommended maximum cumulative dose in Canada is 1000 mg/m2. Preclinical studies did not show any cardioprotectant effect for dexrazoxane when used with mitoxantrone, and no clinical studies have been done. Therefore, dexrazoxane is not recommended for use with mitoxantrone. There is no evidence for or against the use of dexrazoxane in the adjuvant setting for any tumour type. Because of concerns that dexrazoxane may reduce the efficacy of anthracyclines, and because data are not yet available on long-term toxicities, further studies should be performed before the drug is used in this setting." @default.
• W82259717 created "2016-06-24" @default.
• W82259717 creator A5011219577 @default.
• W82259717 creator A5037488348 @default.
• W82259717 creator A5044291041 @default.
• W82259717 date "1999-04-01" @default.
• W82259717 modified "2023-10-01" @default.
• W82259717 title "Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group." @default.
• W82259717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10474762" @default.
• W82259717 hasPublicationYear "1999" @default.
• W82259717 type Work @default.
• W82259717 sameAs 82259717 @default.
• W82259717 citedByCount "26" @default.
• W82259717 countsByYear W822597172012 @default.
• W82259717 countsByYear W822597172013 @default.
• W82259717 countsByYear W822597172014 @default.
• W82259717 countsByYear W822597172016 @default.
• W82259717 countsByYear W822597172017 @default.
• W82259717 countsByYear W822597172018 @default.
• W82259717 countsByYear W822597172019 @default.
• W82259717 countsByYear W822597172021 @default.
• W82259717 countsByYear W822597172022 @default.
• W82259717 countsByYear W822597172023 @default.
• W82259717 crossrefType "journal-article" @default.
• W82259717 hasAuthorship W82259717A5011219577 @default.
• W82259717 hasAuthorship W82259717A5037488348 @default.
• W82259717 hasAuthorship W82259717A5044291041 @default.
• W82259717 hasConcept C121608353 @default.
• W82259717 hasConcept C126322002 @default.
• W82259717 hasConcept C143998085 @default.
• W82259717 hasConcept C168563851 @default.
• W82259717 hasConcept C177713679 @default.
• W82259717 hasConcept C2776694085 @default.
• W82259717 hasConcept C2776802502 @default.
• W82259717 hasConcept C2778233292 @default.
• W82259717 hasConcept C2779720357 @default.
• W82259717 hasConcept C2780835546 @default.
• W82259717 hasConcept C530470458 @default.
• W82259717 hasConcept C535046627 @default.
• W82259717 hasConcept C71924100 @default.
• W82259717 hasConceptScore W82259717C121608353 @default.
• W82259717 hasConceptScore W82259717C126322002 @default.
• W82259717 hasConceptScore W82259717C143998085 @default.
• W82259717 hasConceptScore W82259717C168563851 @default.
• W82259717 hasConceptScore W82259717C177713679 @default.
• W82259717 hasConceptScore W82259717C2776694085 @default.
• W82259717 hasConceptScore W82259717C2776802502 @default.
• W82259717 hasConceptScore W82259717C2778233292 @default.
• W82259717 hasConceptScore W82259717C2779720357 @default.
• W82259717 hasConceptScore W82259717C2780835546 @default.
• W82259717 hasConceptScore W82259717C530470458 @default.
• W82259717 hasConceptScore W82259717C535046627 @default.
• W82259717 hasConceptScore W82259717C71924100 @default.
• W82259717 hasIssue "2" @default.
• W82259717 hasLocation W822597171 @default.
• W82259717 hasOpenAccess W82259717 @default.
• W82259717 hasPrimaryLocation W822597171 @default.
• W82259717 hasRelatedWork W194466123 @default.
• W82259717 hasRelatedWork W2021985387 @default.
• W82259717 hasRelatedWork W2127753540 @default.
• W82259717 hasRelatedWork W2139399232 @default.
• W82259717 hasRelatedWork W2225859329 @default.
• W82259717 hasRelatedWork W2362550559 @default.
• W82259717 hasRelatedWork W2370878878 @default.
• W82259717 hasRelatedWork W2393841721 @default.
• W82259717 hasRelatedWork W2440267131 @default.
• W82259717 hasRelatedWork W2394572696 @default.
• W82259717 hasVolume "3" @default.
• W82259717 isParatext "false" @default.
• W82259717 isRetracted "false" @default.
• W82259717 magId "82259717" @default.
• W82259717 workType "article" @default.